144 related articles for article (PubMed ID: 31546749)
1. Efficient Epidermal Growth Factor Receptor Targeting Oligonucleotide as a Potential Molecule for Targeted Cancer Therapy.
Wang T; Philippovich S; Mao J; Veedu RN
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31546749
[TBL] [Abstract][Full Text] [Related]
2. A neutralizing RNA aptamer against EGFR causes selective apoptotic cell death.
Esposito CL; Passaro D; Longobardo I; Condorelli G; Marotta P; Affuso A; de Franciscis V; Cerchia L
PLoS One; 2011; 6(9):e24071. PubMed ID: 21915281
[TBL] [Abstract][Full Text] [Related]
3. Synergistic Targeting HER2 and EGFR with Bivalent Aptamer-siRNA Chimera Efficiently Inhibits HER2-Positive Tumor Growth.
Xue L; Maihle NJ; Yu X; Tang SC; Liu HY
Mol Pharm; 2018 Nov; 15(11):4801-4813. PubMed ID: 30222359
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of cell proliferation by an anti-EGFR aptamer.
Li N; Nguyen HH; Byrom M; Ellington AD
PLoS One; 2011; 6(6):e20299. PubMed ID: 21687663
[TBL] [Abstract][Full Text] [Related]
5. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
[TBL] [Abstract][Full Text] [Related]
6. A low-molecular-weight compound exerts anticancer activity against breast and lung cancers by disrupting EGFR/Eps8 complex formation.
Li M; Yang J; Zhang L; Tu S; Zhou X; Tan Z; Zhou W; He Y; Li Y
J Exp Clin Cancer Res; 2019 May; 38(1):211. PubMed ID: 31118055
[TBL] [Abstract][Full Text] [Related]
7. Targeting VEGF with LNA-stabilized G-rich oligonucleotide for efficient breast cancer inhibition.
Edwards SL; Poongavanam V; Kanwar JR; Roy K; Hillman KM; Prasad N; Leth-Larsen R; Petersen M; Marušič M; Plavec J; Wengel J; Veedu RN
Chem Commun (Camb); 2015 Jun; 51(46):9499-502. PubMed ID: 25968110
[TBL] [Abstract][Full Text] [Related]
8. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
9. The marine-derived pachycladin diterpenoids as novel inhibitors of wild-type and mutant EGFR.
Mohyeldin MM; Akl MR; Siddique AB; Hassan HM; El Sayed KA
Biochem Pharmacol; 2017 Feb; 126():51-68. PubMed ID: 27940262
[TBL] [Abstract][Full Text] [Related]
10. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
11. Combined Treatment with Triptolide and Tyrosine Kinase Inhibitors Synergistically Enhances Apoptosis in Non-small Cell Lung Cancer H1975 Cells but Not H1299 Cells through EGFR/Akt Pathway.
Tong X; Jiang P; Li Y; Guo L; Zhang HM; Zhang BK; Yan M
Chem Pharm Bull (Tokyo); 2019 Aug; 67(8):864-871. PubMed ID: 31142691
[TBL] [Abstract][Full Text] [Related]
12. Effect of additional inhibition of human epidermal growth factor receptor 2 with the bispecific tyrosine kinase inhibitor AEE788 on the resistance to specific EGFR inhibition in glioma cells.
Berezowska S; Diermeier-Daucher S; Brockhoff G; Busch R; Duyster J; Grosu AL; Schlegel J
Int J Mol Med; 2010 Nov; 26(5):713-21. PubMed ID: 20878094
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A.
Ciardiello F; Damiano V; Bianco R; Bianco C; Fontanini G; De Laurentiis M; De Placido S; Mendelsohn J; Bianco AR; Tortora G
J Natl Cancer Inst; 1996 Dec; 88(23):1770-6. PubMed ID: 8944008
[TBL] [Abstract][Full Text] [Related]
14. The epidermal growth factor receptor as a therapeutic target in glioblastoma multiforme and other malignant neoplasms.
Loew S; Schmidt U; Unterberg A; Halatsch ME
Anticancer Agents Med Chem; 2009 Jul; 9(6):703-15. PubMed ID: 19601750
[TBL] [Abstract][Full Text] [Related]
15. Study of the Function of G-Rich Aptamers Selected for Lung Adenocarcinoma.
Hu J; Zhao Z; Liu Q; Ye M; Hu B; Wang J; Tan W
Chem Asian J; 2015 Jul; 10(7):1519-25. PubMed ID: 25864879
[TBL] [Abstract][Full Text] [Related]
16. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L
Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476
[TBL] [Abstract][Full Text] [Related]
17. The FGF2 aptamer inhibits the growth of FGF2-FGFR pathway driven lung cancer cells.
Hamamoto J; Yasuda H; Nonaka Y; Fujiwara M; Nakamura Y; Soejima K; Betsuyaku T
Biochem Biophys Res Commun; 2018 Sep; 503(3):1330-1334. PubMed ID: 30005872
[TBL] [Abstract][Full Text] [Related]
18. EGFR aptamer-conjugated liposome-polycation-DNA complex for targeted delivery of SATB1 small interfering RNA to choriocarcinoma cells.
Dong J; Cao Y; Shen H; Ma Q; Mao S; Li S; Sun J
Biomed Pharmacother; 2018 Nov; 107():849-859. PubMed ID: 30142547
[TBL] [Abstract][Full Text] [Related]
19. The epidermal growth factor receptor in malignant gliomas: pathogenesis and therapeutic implications.
Nakamura JL
Expert Opin Ther Targets; 2007 Apr; 11(4):463-72. PubMed ID: 17373877
[TBL] [Abstract][Full Text] [Related]
20. RNA Aptamers for Theranostics of Glioblastoma of Human Brain.
Kopylov AM; Fab LV; Antipova O; Savchenko EA; Revishchin AV; Parshina VV; Pavlova SV; Kireev II; Golovin AV; Usachev DY; Pavlova GV
Biochemistry (Mosc); 2021 Aug; 86(8):1012-1024. PubMed ID: 34488577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]